Search Bar & Filters
Found 25 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
This research aims to compare how the body processes the drug MK-1406 when given as two injections versus three injections in healthy adult participants. The study also evaluates the safety and how well participants tolerate MK-1406. It is a Phase 1 clinical trial designed to gather important early information about the drugs behavior and effects. Participants receive MK-1406 through subcutaneous injections administered either as three injections or two injections on the first day of the study. The study uses a randomized, open-label, parallel group design, meaning participants are randomly assigned to one of the two groups and both researchers and participants know which treatment is given. During the study, researchers monitor participants for up to four weeks after dosing to measure how much MK-1406 is in the blood over time and observe any side effects or injection site reactions. Participants are followed for about 43 days to record any adverse events or if they stop the study due to side effects. Safety and tolerability are carefully assessed throughout the trial.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and effectiveness of two drugs, inebilizumab and blinatumomab, in adults with active and treatment-resistant autoimmune diseases, including systemic lupus erythematosus SLE with nephritis and rheumatoid arthritis RA. This Phase 2 trial includes several subprotocols to study these medications in different patient groups and disease conditions. Participants may receive inebilizumab through intravenous infusions in either three or four doses, or blinatumomab via subcutaneous injections at low, medium, or high doses. The trial includes parts where doses are determined based on earlier results. The treatments are studied in subgroups of patients with SLE with or without nephritis and in patients with active refractory RA. Throughout the study, participants will be monitored for treatment-emergent adverse events and serious adverse events up to 52 weeks. Various clinical measures for kidney response, disease remission, and disease activity scores will be assessed at multiple time points. Safety, drug levels, antibody formation, and disease activity changes will be tracked regularly, with a total study duration extending up to 52 weeks for outcome evaluations.
Actively Recruiting
Researchers are evaluating the effects of BGE-102 on vision changes in adults with center-involved diabetic macular edema CI-DME. This phase 2 study aims to assess how BGE-102, alone or combined with an anti-vascular endothelial growth factor anti-VEGF drug, affects ocular health and vision over a 12-week treatment period. The study also monitors the safety and tolerability of BGE-102. Participants will be randomly assigned to one of three groups BGE-102 capsules taken once daily combined with sham injections, BGE-102 capsules combined with anti-VEGF injections every four weeks, or placebo capsules combined with anti-VEGF injections every four weeks. The total treatment lasts up to 12 weeks. The study includes a screening period up to 4 weeks and a 4-week follow-up after treatment ends. During the approximately 20-week study, participants attend visits every two weeks for the first month of treatment, then every four weeks until week 16. Researchers will evaluate vision using best corrected visual acuity at week 12 as the main outcome. Safety is also carefully monitored through adverse event tracking up to week 16. Participants may undergo eye charts, retinal scans, and other ocular assessments throughout the study.
Actively Recruiting
Researchers are studying the safety, tolerability, how the body processes, and potential disease-modifying effects of a drug called BMS-986528 in adults with refractory, difficult-to-treat rheumatoid arthritis RA. This early-phase trial aims to gather initial data on the drugs impact in this group of patients. The study is sponsored by Bristol-Myers Squibb and focuses on participants aged 18 to 65 with this challenging form of RA. Participants receive specified doses of BMS-986528 on certain days during the trial. The study includes multiple experimental cohorts, each receiving the drug under close monitoring. Throughout the treatment period, various measurements are taken to assess how the drug behaves in the body, including concentrations and clearance, as well as its effects on immune cells and antibody levels. During the study, participants are regularly assessed for any treatment-emergent side effects and serious adverse events up to week 54. Researchers also evaluate changes in disease activity scores and immune system markers. These evaluations involve blood tests and clinical assessments to monitor safety and potential benefits. The entire participation period extends up to approximately 54 weeks, allowing for comprehensive observation.
Actively Recruiting
Researchers are investigating the long-term effectiveness, safety, and tolerability of once-daily oral ASC30 compared to a placebo in adults with obesity or overweight and type 2 diabetes mellitus T2DM. This Phase III, global, randomized, double-blind, placebo-controlled study seeks to understand how different maintenance doses of ASC30 impact these participants over time. Participants will be randomly assigned to receive one of three doses of oral ASC30 tablets or matching placebo tablets once daily. The study compares these groups to evaluate the effects of ASC30 on weight and metabolic health over a 72-week period. Treatment is administered daily by mouth throughout the study. During participation, individuals will undergo regular assessments including measurements of body weight, blood sugar control HbA1c and fasting glucose, blood pressure, cholesterol, triglycerides, insulin levels, waist circumference, and body mass index. The main outcome is the percent change in body weight from the start to week 72. Safety and tolerability will be closely monitored, and the entire study duration spans about 72 weeks from baseline to final evaluation.
Actively Recruiting
Researchers are conducting a global Phase III clinical trial to evaluate the long-term effects of ASC30, an oral medication taken once daily, in adults with obesity or overweight who also have weight-related health conditions but do not have type 2 diabetes. The study aims to compare the efficacy, safety, and tolerability of three different maintenance doses of ASC30 against a placebo. This randomized, double-blind, placebo-controlled trial focuses on assessing body weight changes and related health measures over a lengthy period. Participants in this trial will be randomly assigned to one of four groups three groups receive different doses of ASC30 tablets daily, and one group receives matching placebo tablets daily. The treatment period is planned to last 72 weeks, during which participants will take their assigned oral tablets once a day. The study carefully monitors participants throughout the treatment phase to evaluate the effects of the medication compared to placebo. During the trial, participants will undergo regular assessments including measurements of body weight, waist circumference, blood pressure, blood glucose, cholesterol, insulin, and other metabolic markers from baseline through week 72. Researchers will also track safety and tolerability over this period. Participants can expect scheduled visits and evaluations to monitor changes in their health and response to the study medication over the roughly 1.5-year treatment duration.
Actively Recruiting
Healthy Volunteer
Researchers are studying the safety and immune response of the V132 vaccine in healthy older adults aged 50 to 75 years. This Phase 1, randomized, double-blind, comparator-controlled trial aims to evaluate different dose levels of V132 vaccine formulations compared to existing pneumococcal vaccines. The study focuses on understanding how well V132 is tolerated and how it stimulates the immune system in this healthy adult population. Participants will receive single intramuscular doses of one of three V132 vaccine formulations or one of two active comparator vaccines, PREVNAR 20 or CAPVAXIVE, at varying dose levels. The doses for part 2 of the study will be chosen based on safety and immune response data from part 1 and will not exceed the highest dose tested initially. The study includes two parts a dose escalation phase and a dose expansion phase. During the study, participants will be monitored closely for immediate reactions within 30 minutes of vaccination, injection-site and systemic side effects up to 7 days after vaccination, and other adverse events for up to 12 months. Immune response will be measured by specific antibody activity before and 28 days after vaccination. The total study duration extends up to 12 months to ensure comprehensive safety and immunogenicity assessment in healthy older adults.
Actively Recruiting
This research aims to assess the levels of bimekizumab, a drug used for conditions like moderate to severe plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa, in mature breast milk from mothers who are receiving treatment. The studys primary focus is to understand how much bimekizumab is present in breast milk over several days. This is a phase 1, multicenter, open-label, prospective study sponsored by UCB Biopharma SRL. Participants in this study are breastfeeding mothers already treated with commercially available bimekizumab under their physicians care. They will continue their regular treatment and breastfeeding as usual. The study will collect breast milk samples on multiple days spanning from Day 1 to Day 57 to measure the concentration of bimekizumab. The study does not involve changing the treatment but monitors the drug levels in breast milk during the sampling period. During the study, participants will provide breast milk samples on specific days to allow researchers to measure bimekizumab concentrations and estimate the infants dosage through breastfeeding. The study also tracks any adverse events experienced by the mother from consent through approximately 17 weeks. Participants will be monitored throughout the sampling period, and the total participation lasts until all scheduled milk collections and safety follow-ups are completed.
Actively Recruiting
Researchers are evaluating ELV001 as an add-on therapy for adults with active rheumatoid arthritis who have not responded adequately to methotrexate and tumor necrosis factor inhibitors. This Phase 2 randomized, double-blind, placebo-controlled study aims to assess the safety and effectiveness of different doses of ELV001. Approximately 180 to 220 participants aged 18 to 75 years will be enrolled. Participants will be assigned to one of four groups placebo, ELV001 25 mg, 75 mg, or 125 mg daily. The study includes a 4-week screening period, a 12-week double-blind placebo-controlled treatment phase, followed by a 12-week extension where some participants receive higher doses of ELV001. A 4-week safety follow-up concludes the 32-week study. During the study, participants will undergo regular assessments including disease activity scoring, joint counts, blood tests, vital signs, electrocardiograms, and questionnaires about health and function. Researchers will monitor adverse events and drug levels in the blood. The main outcome measured is the change in disease activity score from baseline to week 12. Safety and efficacy will be tracked through week 28, with total participation lasting up to 32 weeks.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and tolerability of two new vaccines, V350A and V350B, designed to prevent diseases related to Epstein Barr virus EBV, a virus linked to infectious mononucleosis, certain cancers, and multiple sclerosis. This Phase 1 trial involves healthy participants aged 12 to 30 years and aims to understand how well these vaccines are tolerated and their immune response. Participants are randomly assigned to receive one of three treatments V350A vaccine, V350B vaccine, or a placebo. Each participant will receive three vaccinations administered by intramuscular injection on Day 1, Month 2, and Month 6. The study follows a sequential design and uses a triple-blind setup to ensure unbiased results. During the study, participants will be closely monitored for side effects related to the injections up to 18 months. Researchers will record injection site reactions, systemic symptoms, immediate and unsolicited adverse events, as well as serious and medically attended adverse events. Immune responses will be measured by antibody levels against EBV antigens. The total participation duration spans up to approximately 18 months, including safety and immune response evaluations.
1-10 of 25
1